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Transcatheter Aortic Valve Replacement
Part 1: Basic Anatomy, Imaging, Sheaths, Wires, and Access Routes
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Melanie Freeman, MBBS,* Marco Barbanti, MD,* Robin H. Heijmen, MD, PHD,z
David A. Wood, MD,* John G. Webb, MD*
Vancouver, British Columbia, Canada; Lucerne, Switzerland; and Nieuwegein, the NetherlandsTranscatheter aortic valve implantation (TAVI) has emerged as a new therapy for patients with severe
aortic stenosis who are inoperable or at very high risk of open heart surgery. Vascular complications are
a potential limitation of TAVI and have been associated with bleeding, transfusions, and mortality.
Transfemoral TAVI can be considered the least invasive approach and is therefore the most widely used
access for TAVI. With the current 18-F to 24-F sheaths, the majority of patients can be treated via the
transfemoral route. Initially, open surgical access was routinely used to introduce the large sheaths and
catheters. Subsequently, percutaneous techniques have emerged as the new standard, resulting in
a less invasive, fully percutaneous procedure. Stiff wires allow insertion of the sheath and delivery of the
device without causing trauma to the artery. Given the high burden of vascular disease in TAVI
candidates, increasing the effectiveness of pre-procedural screening is key. This often begins with
conventional angiography, but computed tomography allows visualization of the artery in 3 dimensions,
thereby overcoming some of the limitations of conventional angiography. Approximately one third of
patients do not have adequate anatomy to allow safe transfemoral access. In such patients, alternative
access routes such as the transapical, transaxillary, or direct aortic access are preferred. These alternative
routes all have speciﬁc advantages and disadvantages. (J Am Coll Cardiol Intv 2013;6:643–53)
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transarterial access, wires, different access routes,
and closure techniques.Evaluation of Vascular Access
Femoral access anatomy. The infrarenal abdominal
aorta bifurcates into the right and left common iliac
arteries that, in turn, bifurcate into the external
and internal iliac arteries. The external iliac passes
under the inguinal ligament, at which point, it is
referred to as the common femoral artery. The
common femoral artery further bifurcates into the
superﬁcial and deep (profunda) femoral arteries.
The inferior epigastric artery arises from the
external iliac artery, superior to the inguinal ligament
(Fig. 1).Apuncture at or above the level of the inferior
epigastric artery is often noncompressible and
increases the risk of retroperitoneal hemorrhage.
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644However, retroperitoneal bleeding can develop after arterial
puncture below the inguinal ligament should the puncture
channel involve both extraperitoneal and retroperitoneal
tissue (5). A puncture below the femoral bifurcation increases
the risk of puncture in a smaller artery and is relatively
noncompressible due to the lack of sufﬁcient support from the
femoral head (6). This may explain the higher risk of pseu-
doaneurysm formation (7). For percutaneous sheath insertion,
a common femoral puncture between the inferior epigastric
artery and the femoral bifurcation is desirable.
In the absence of atherosclerotic disease, the common
femoral artery is compliant and can accommodate sheaths
slightly larger than the artery diameter. In the presence of
moderate or severe calciﬁcation, the external sheath size
should not extend the minimal artery diameter. With the
current 18-F to 19-F sheaths, iliofemoral arteries are large
enough in the majority of patients evaluated for TAVI.
Conventional angiography. Given the high burden of vascular
complications in TAVI, increasing the effectiveness of pre-Abbreviations
and Acronyms
DSA = digital subtraction
angiography
GFR = glomerular ﬁltration
rate
IVUS = intravascular
ultrasound
MDCT = multidetector
computed tomography
MRA = magnetic resonance
angiography
TAVI = transcatheter aortic
valve implantationprocedural screening of patients
for TAVI is key. This often begins
with conventional angiography as
virtually all patients undergo cor-
onary angiography. A calibrated
pigtail (e.g., Beacon Tip Royal
Flush, Cook Medical Inc., Bloo-
mington, Indiana) is placed in the
abdominal aorta just above the
bifurcation. With injection of 20
to 35 ml of contrast dye overw2 s,
both iliac and femoral arteries
can be visualized. The common
femoral artery and the level of the
femoral bifurcation in relation to
the femoral head should beassessed. Localized femoral disease, extensive calciﬁcation,
or a high femoral bifurcation may inﬂuence the site of
puncture and reliability of closure. Using the catheter
markers for calibration, the minimal lumen diameter of the
iliac and femoral arteries on both sides can be measured.
The advantages of angiography are its high spatial reso-
lution and that vessel movement can be evaluated and the
degree of calciﬁcation can be estimated before the dye arrives.
Limited vessel movement may indicate a more rigid and
more calciﬁed artery. Angiography provides only a limited
evaluation of atherosclerotic disease burden as well as the
degree of vessel tortuosity.
Digital subtraction angiography (DSA) is still considered
the reference gold standard on the basis of its superior spatial
resolution (8,9). However, both angiography and DSA
depict arterial anatomy in a 2-dimensional plane particularly
when rotational angiography is not performed. As a result,
a stenosis that is only visible in the third dimension may be
missed.Computed tomography. Multidetector computed tomog-
raphy (MDCT) allows high spatial resolution in 3 dimen-
sions and rapid image acquisition, thereby overcoming some
of the limitations of conventional angiography and DSA.
Using a centerline approach to elongate the vessel image,
multiple luminal measurements should be made in a plane
orthogonal to the vessel rather than in the transverse axial
plane. Using this approach, MDCT can evaluate vessel size,
degree of calciﬁcation, minimal luminal diameter, plaque
burden, and vessel tortuosity and also identify high-risk
features including dissections and complex atheroma. In
addition, MDCT is becoming the gold standard for annular
sizing and may be used for coronary artery assessment (10).
Approximately 80 to 120 ml of intravenous contrast is
usually injected for visualization of the iliofemoral arteries
(11). In a recent study of patients undergoing MDCT, the
incidence of contrast-induced nephropathy was 0.6% in
those with a glomerular ﬁltration rate (GFR) of 40 to 60
ml/min and 7.8% in those with a GFR <30 ml/min (8).
Therefore, MDCT is often not performed in patients with
severe renal insufﬁciency (12).
To help reduce the risk of contrast-induced nephropathy,
a number of contrast-reducing techniques have been pub-
lished. Kubo et al. (13) reported that administration of 50 ml
of contrast resulted in adequate contrast enhancement
throughout the thoracoabdominal-aortoiliac system. Alter-
natively, direct arterial injection through a 4-F to 5-F pigtail
catheter allows visualization of both iliofemoral arteries with
only 10 to 20 ml of contrast (14). MDCT can be performed
right after diagnostic angiography with the patient trans-
ferred with the sheath and pigtail catheter secured in place.
MDCT can also be performed without contrast dye.
Although estimates of luminal diameter may be less reliable,
this still provides detail regarding calciﬁcation.
In a recent meta-analysis, MDCT had a sensitivity of
92% and a speciﬁcity of 93% to detect a 50% stenosis
compared with DSA (9). In patients with heavily calciﬁed
arteries, overestimation of the plaque size and stenosis
severity may occur (blooming/partial volume averaging),
resulting in the underestimation of the minimal luminal
diameter (15).
Magnetic resonance angiography. Magnetic resonance
angiography (MRA) has the advantage of vascular screening
with a low risk of nephrotoxicity, although its resolution is
lower than that of MDCT (8). A recent meta-analysis found
that MRA is very accurate for the detection of 50%
stenoses with a median sensitivity of 95% and a median
speciﬁcity of 97% (16). MRA without contrast enhancement
may be a promising alternative, particularly for those patients
with signiﬁcant renal impairment (GFR <30 ml/min) to
help reduce the potential risk of gadolinium-mediated
nephrogenic systemic ﬁbrosis. A recent study showed that
nonenhanced MRA correlated very well with contrast-
enhanced MRA (17).
Figure 1. Basic Iliofemoral Anatomy
The external iliac artery passes under the inguinal ligament, at which point it is renamed the common femoral artery. The inferior epigastric artery arises from the
external iliac artery, just above the inguinal ligament and serves as a useful landmark to demarcate the retroperitoneal space (A). The average minimal artery diameter
of the common iliac artery, the external iliac artery, and the common femoral artery are shown (B).
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645Intravascular ultrasound. Intravascular ultrasound (IVUS)
(Volcano Corp., Rancho Cordova, California, or Boston
Scientiﬁc, Natick, Massachusetts) has the advantage of
a very high resolution and allows vessel examination in all 3
dimensions. In addition, plaque composition and volume
can be assessed without blooming artifacts from calciﬁca-
tions that sometimes reduce the quality of MDCT. It is also
possible to differentiate between circular and noncircular
plaques. In a study comparing IVUS with angiography,
IVUS yielded comparable luminal diameters and stenosis
measurements. The degree of calciﬁcation was graded less
severe by IVUS (18).
Sheaths
Sheaths allow access to the vessel without loss of blood by
using a haemostatic valve. Long 30- to 35-cm sheaths are
used that are designed to deliver the prosthesis beyond the
iliac artery directly to the aorta.
Sheath diameter has decreased over time. The Medtronic
CoreValve (Medtronic Inc., Minneapolis, Minnesota) saw
a gradual decrease in sheath size from 25-F (ﬁrst generation)
to 18-F (third generation). The Edwards SAPIEN
valve (Edwards Lifesciences, Irvine, California) requires
a 22-F/24-F sheath, and the Edwards SAPIEN XT valve
requires an 18-F/19-F sheath for the 23- and 26-mmvalves. The different sheath types are summarized in
Table 1.
Edwards RetroFlex3 and NovaFlex introducer sheaths. The
Edwards RetroFlex3 introducer sheath (Edwards Life-
sciences) is used for implantation of the Edwards SAPIEN
valve. It has an inner diameter of 22-F and 24-F for the
23- and 26-mm valve, respectively. The corresponding
outer diameters are 8.4 and 9.2 mm. The Edwards Nova-
Flex Introducer Sheath (Edwards Lifesciences) has an inner
diameter of 18-F and 19-F for the 23-mm Edwards
SAPIEN XT and 26-mm Edwards SAPIEN XT, respec-
tively. The corresponding outer diameters are 7.2 mm and
7.5 mm, respectively.
Edwards eSheath expandable introducer sheath. The Ed-
wards eSheath is a 36-cm long expandable sheath with
a compliant seam that allows transient expansion as the
delivery catheter is passed through it. After passage of the
prosthesis, the sheath contracts to some degree toward its
unexpanded size (Fig. 2). The sheath is introduced in its
low-proﬁle conﬁguration, reducing the risk for iliofemoral
injury. When inserting the eSheath with the introducer, the
expansion seam is oriented toward the posterior wall of the
artery being accessed, thus avoiding any damage to the
softer seam by the calciﬁed artery wall. The eSheath is
available in unexpanded inner diameters of 16-F, 18-F, and
20-F for the 23-, 26-, and 29-mm Edwards SAPIEN XT
Table 1. Internal and External Diameter of Large Sheaths
Manufacturer Sheath
Sheath Internal
Diameter, F
Sheath External
Diameter, mm
Edwards Lifesciences RetroFlex 3 introducer sheath 22 8.4
24 9.2
NovaFlex introducer sheath 18 7.2*
19 7.5
Expandable Sheath 14 5.9*
16 6.6*
18 7.2*
20 7.8*
Cook Medical Check-Flo Introducer 18 7.2
St. Jude Medical Ultimum 18 6.8
20 7.6
22 8.2
Onset Medical SoloPath Balloon Expandable
Transfemoral Introducer
19 7.3y
20 7.7y
21 8y
Gore Medical DrySheath 16 6.2
18 6.8
20 7.5
*The pre-expanded diameter is indicated. The fully expanded diameter depends on the size of the catheter that is used for the procedure.
yThe ﬁnal outer diameter is indicated for the SoloPath Balloon Expandable Transfemoral Introducer. The unexpanded outer diameter is 4.3 mm.
Figure 2. Edwards eSheath Expandable Introducer Sheath
The Edwards expandable sheath (1) features a fold that expands as the
NovaFlex catheter moves through (2,3).
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646valves, respectively. Because the sheath transiently expands
and then contracts, there is the possibility of incomplete
arterial sealing. To avoid this, it is best to advance the
sheath all the way into the patient where the larger and
nonexpandable strain relief portion of the sheath provides
reliable sealing.
Check-Flo Sheath. The large Check-Flo sheaths (Cook
Medical) are available with inner diameters of 16-F, 18-F,
20-F, and 22-F and are most frequently used with the
Medtronic CoreValve. The sheath has a working length of
30 cm, but longer sheaths are available.
St. Jude Medical Ultimum Sheath. The Ultimum Sheath (St.
Jude Medical, Inc., St. Paul, Minnesota) is available with
internal diameters of 12-F, 14-F, 18-F, and 20-F. All
sheaths have a working length of 30 cm. There is also a 16-F
sheath available that is 35 cm long as well as a 22-F sheath
with a length of 25 cm.
SoloPath Balloon Expandable Transfemoral Access System. The
SoloPath sheath (Terumo Interventional Systems, Inc.,
Somerset, New Jersey) is a balloon-expandable sheath. It is
available with internal diameters of 18-F, 19-F, and 21-F and
has an expandable length of 25 cm and a working length of 25
to 35 cm. The sheath is inserted in its unexpanded state with
an outer diameter of only 4.3 mm, facilitating delivery through
difﬁcult anatomy. A balloon is then inﬂated to expand
the sheath and reach the intended diameter (18-F to 21-F)
(Fig. 3) (19).
GORE DrySeal Sheath. The GORE DrySeal Sheath (Gore
Medical, Flagstaff, Arizona) is available in different sizes
ranging from 12-F to 26-F and has a working length of28 cm. The sheath has a stopcock, through which 2.5 ml of
saline solution is injected to pressurize the hemostatic
balloon valve. This way, the sheath can accommodate
multiple wires simultaneously with minimal blood loss.Wires
The purpose of the wire is to allow safe delivery of the device
without causing trauma to the artery. Different guidewires
are currently used for TAVI. Currently used wires have
a diameter of 0.035 inch (0.9 mm). Exchange wires with
a length of 260 cm are required to exchange catheters while
Figure 3. The SoloPath Expandable Sheath
(A) The unexpanded sheath has an outer diameter of approximately 4.3 mm. (B) The sheath is then expanded with a balloon to reach its inner diameter of 19-F with an
outer diameter of 7.3 mm. (C,D) The unexpanded sheath is advanced over a stiff wire. (E) The sheath is then expanded. (F) Contralateral injection following the
procedure shows a good result with no vascular damage.
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647keeping the tip of the wire in the left ventricle. The wires are
constructed of an inner stiff core that is tapered distally and
does not extend into the softer, atraumatic, shapeable tip.
Although the guidewires have names such as “extra stiff” or
“super stiff,” these names do not always correlate with the
actual stiffness (e.g., the Lunderquist Extra Stiff wire is
much stiffer than the Amplatz Super Stiff wire) (20). The
very stiff wires may be useful in very tortuous and borderline
anatomy to advance the sheath, but should not be used to
support TAVI. All wires that are currently used have some
sort of coating, most commonly tetraﬂuoroethylene, which
reduces friction considerably. Some have an antithrombo-
genic heparin coating.
Amplatz Extra Stiff Guidewire. The Amplatz Extra Stiff
Guidewire (Cook Medical Inc.), most commonly used for
TAVI, is a heparin-coated stainless steel wire with
a diameter of 0.035 inch (0.9 mm) and a length of 260 cm.
Among commonly used stiff guidewires, the Amplatz Extra
Stiff has the least stiffness (20). The wire has a straight tip
or a small distal J with a radius of 3 mm. The distal 1, 3, or
6 cm of the wire are ﬂexible. To avoid trauma to the left
ventricle, an exaggerated J is usually formed by the inter-
ventionalist. It is important that the stiffer part of the wire
extends into this exaggerated J curve to provide more
stability and to protect the left ventricular wall from trauma
through the nose cone.
Amplatz Super Stiff Guidewire. The Amplatz Super Stiff
Guidewire (Boston Scientiﬁc), is a coated stainless steel wirewith a diameter of 0.035 inch (0.9 mm) and a length of
260 cm. The wire is stiffer than the Amplatz Extra Stiff
Guidewire. It has a straight tip or a small distal J with
a radius of 3 mm and a soft, atraumatic tip 1 to 6 cm in
length. If a guidewire with a soft tip of 7 cm is used, the
exaggerated J has to be formed with several loops to ensure
that the stiffer part of the wire extends into the exaggerated J
curve. This wire is widely used in centers that implant the
Medtronic CoreValve.
Backup Meier Guidewire. The Meier wire (Boston Scien-
tiﬁc) is a coated stainless steel wire with a diameter of
0.035 inch (0.9 mm) and a length of 260 cm. It has
a greater shaft stiffness than the Amplatz Extra Stiff and
Super Stiff guidewires. The length of the ﬂexible tip is
10 cm.
Hi-Torque Supra Core 35 Guidewire. The Hi-Torque
Supracore wire (Abbott Vascular Inc., Redwood City,
California), has a 1-to-1 torque response for improved
steerability. The wire has a length of 300 cm and a diameter
of 0.035 inch (0.9 mm).
Lunderquist Extra Stiff. In case of extensive tortousity,
extremely stiff guidewires such as a Lunderquist Extra Stiff
guidewire (Cook Medical Inc.) are used. The Lunderquist
guidewire is a coated stainless steel wire with a diameter of
0.035 inch (0.9 mm) and a length of 260 cm. It has a 4-cm
ﬂexible J-shaped tip. The guidewire is stiffer than the
Amplatz Extra Stiff and Super Stiff Guidewires and the
Meier Guidewire.
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648Transfemoral Access
Transfemoral access is considered the access of choice due
to its least invasive nature and is feasible in the majority
of patients undergoing TAVI. Most interventional car-
diologists are very familiar with the transfemoral route due
to their experience with percutaneous coronary interven-
tion. Although sheath size is decreasing with newer
generation valves, some patients have unfavorable iliofe-
moral arteries that warrant an alternative access route (21).
In such patients, the options are the transapical (currently
mainly used with the Edwards SAPIEN, SAPIEN XT,
and next generation valves) and the direct aortic, trans-
axillary, or subclavian access (mainly for the Medtronic
CoreValve) (22).
Transfemoral access with a surgical cutdown. With the
initial very large diameter sheaths (22-F to 24-F), early
studies used a surgical cutdown to expose the iliofemoral
artery for transfemoral access (1,23–25). A planned surgical
cutdown can be performed at the beginning of the proce-
dure to allow visualization and selection of the ideal
puncture site and control of the artery above and below the
puncture. Alternatively, a percutaneous puncture is per-
formed, and the artery is exposed for closure only. Although
most of transfemoral procedures are now performed
percutaneously, a surgical cutdown might still be desirable
in very obese patients, where there is a femoral graft or stent
or where a high puncture is needed due to a high femoral
bifurcation (26).
Percutaneous transfemoral access. For adequate functioning
of the available suture-mediated closure devices, a precise
puncture in the center of the lumen is important. Usually,Figure 4. Puncture Guided by Hemostat, Pigtail, or Sonography
(A) To determine the exact puncture site, a radiopaque object can be placed over t
contralateral femoral artery and used as a target or for contrast injections to facilita
a puncture in the middle of the common femoral artery (asterisk).a puncture of the common femoral artery in the middle of
the femoral head is desirable. There are several ways to
achieve this. A hemostat can be placed over the approximate
middle of the femoral head. Fluoroscopy is needed to ﬁnd
the exact position. The puncture is then performed a bit
lower, aiming to hit the artery in the middle of the femoral
head. Another method is to position a catheter from the
contralateral side. With small bolus injections, the common
femoral artery is visualized. Alternatively, the tip of the
catheter can be positioned in the targeted area. Puncture is
then performed under ﬂuoroscopy, aiming for the tip of the
catheter. Many use ultrasound to visualize the artery and
guide puncture (Fig. 4). In a previous study, ultrasound-
guided access reduced complication rates and procedural
time in endovascular aortic aneurysm repair (27). The
micropuncture technique (Micropuncture Introducer Set,
Cook Medical Inc.) can be used to obtain access in TAVI.
However, a recent publication suggested that the rate of
retroperitoneal bleeding may be increased due to the angled
tip of the micropuncture guide wire, which tended to be
diverted from the main vessel to the small side branches of
the femoral or iliac arteries (28). Other ways to achieve
a puncture in the middle of the femoral head are using DSA
and road mapping as well as real-time crossover angiog-
raphy. With these techniques, the needle can be manipu-
lated under ﬂuoroscopy with reference to the arterial wall
and lumen.
Percutaneous preclosure and closure. The ﬁrst cases of
percutaneous closure using the ProStar device (Abbott
Vascular Inc.) were reported in 1996 (29). Later, to reduce
the invasiveness of endovascular aortic aneurysm repair, the
ProStar and Perclose devices were used off-label to preclosehe femoral head. (B) Alternatively, a catheter can be introduced from the
te puncture under ﬂuoroscopy. (C) Finally, ultrasound can be used to achieve
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649the femoral artery (30). This was initially done with surgical
exposure and direct visualization of the femoral artery using
2 ProStar devices (30) and later without a cutdown, resulting
in totally percutaneous aortic aneurysm repair (31,32).
Totally percutaneous endovascular aneurysm repair was
found to be associated with a lower rate of late groin
complications, shorter procedure time, and less severe scar
tissue formation (32,33).
Percutaneous closure has been increasingly used
(12,24,34–41). A fully percutaneous procedure facilitates
performing the procedure with the patient under conscious
sedation with local anesthesia and allows earlier patient
ambulation (42,43).
Suture-based closure devices have high success and very
low vascular complication rates after percutaneous coronary
angioplasty with 6-F to 8-F sheaths (42,44,45). In TAVI,
the larger caliber sheaths used require a more careful closure.
To maintain access to the artery, a guidewire should be left
in place while removing the large sheath. The blood pressure
should be monitored for rapid detection of signs of perfo-
ration such as hypotension and/or tachycardia because large
volumes of blood loss may enter the retroperitoneal space
without being noticed at the puncture site. Once the sheath
is removed, the ProGlide or ProStar sutures are tightened.
To prevent a sudden gulp of blood and a subsequent sudden
pull on the sutures tearing the vascular wall, the dilator may
be reintroduced carefully to allow a gradual closure of theFigure 5. Percutaneous Closure With 2 ProGlides
(A,B) Sutures are deployed at 10 and 2 o’clock positions. (C) A 16-F dilator is inserte
inserted under ﬂuoroscopy (E). After implantation of the valve, the sheath is retrieve
hemostasis is achieved and the sutures are further tightened using the knot pusherartery with continuous pulling on the sutures. If hemostasis
is accomplished, the guidewire is removed and the sutures
are further tightened. This way, access to the artery is
preserved in case of possible closure failure. Completion
angiography from the contralateral side may be performed to
ensure integrity of the iliofemoral arteries. Postprocedural
death from unrecognized iliac rupture has been reported in
the literature (46).
Perclose Proglide. Figure 5 illustrates percutaneous closure
with 2 Proglides. Usually, the femoral artery is punctured
and dilated with a standard arterial sheath. Then, the Pro-
glide device is advanced over the guidewire, and the ﬁrst
suture is deployed slightly angulated at the 10 o’clock
position. Guidewire access is maintained, and a second
Proglide device is inserted and deployed at the 2 o’clock
position. The regular J wire is now exchanged for a stiffer
wire, and the large sheath is advanced under ﬂuoroscopy.
After conclusion of the procedure, the introducer sheath is
slowly removed, but the guidewire is left to maintain access.
The sutures are tightened. In case of sufﬁcient hemostasis,
the guidewire can be removed and the sutures are further
tightened using the knot pusher to ensure approximation of
the knot to the vessel wall. Should hemostasis fail, it is
possible to implant a third (or fourth) Proglide over the
guidewire.
ProStar. Figure 6 illustrates percutaneous closure with the
ProStar device. The 10-F ProStar device is advanced overd. The regular J wire is exchanged for a stiffer wire (D), and the large sheath is
d (F), and the sutures are tightened (G). (H,I) The wire is removed if sufﬁcient
.
Figure 6. ProStar XL Deployment
After dissecting the subcutaneous upper and lower art of the introducer (Step 1, arrow), the Prostar is inserted until a pulsatile blood ﬂow came from the straight tube
(Step 2, arrow), maintaining the position using the left hand (Step 3, asterisk). With the right hand, the needles are extract and, once removed, cut from the suture
lines (Steps 4 and 5). At this point, the Prostar is pulled out, and the guidewire is reinserted, with repositioning of the 9-F introducer (Step 6).
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650the guidewire until the dedicated marker lumen shows blood
marking indicating that the sutures and needles are within
the vessel lumen. The 4 needles are pulled back while
maintaining the position and entry angle of the ProStar
device. The sutures are removed from the hub, taking care to
identify the upper and lower sets of sutures. The device is
retracted, and the guidewire is reinserted through the
guidewire port. Then the device is removed, and a dilator is
inserted. As described earlier, the J guidewire can be
exchanged for a stiffer guidewire to insert the large sheath.
At the end of the procedure, the sutures are tied with
a sliding knot and the knot pusher (47). Both the ProStar
and ProGlide devices require experience, and there is
a signiﬁcant learning curve. With experience, it should be
possible to achieve a success rate >90% (12,48).
Crossover balloon occlusion. If necessary, the iliac or
femoral artery hemostasis can be achieved using a con-
tralaterally introduced 8- to 12-mm peripheral angioplasty
balloon. Prophylactic placement of a crossover sheath or
balloon may be advisable when percutaneous closure is
considered to be more likely, as with larger 22-/24-F
sheaths, very obese patients, or difﬁcult pre-closure (49,50).
Protamine. Heparin reversal with protamine may be helpful if
there is persistent oozing. However, this is rarely necessary and
may increase the risk of femoral artery thrombosis, particularly
when femoral compression is also used (49) (Fig. 7).
Alternative Access Routes
Transapical access. A left anterolateral mini-thoracotomy in
the ﬁfth or eventually in the sixth intercostal space is per-
formed. Using minimal rib spreading, the apex of the leftventricle can be exposed after opening the pericardium. The
deﬁnite location of entry is chosen slightly lateral and
anterior to the true apex aiming at muscular tissue that
provides sufﬁcient strength. Access is obtained through 2
purse-string sutures with interrupted felt pledgets with
sufﬁcient depth but without tearing of the myocardium.
After deployment of the valve, the left ventricular sheath is
removed, and hemostasis is secured with the previously
placed pledgeted sutures (51). Additional Teﬂon-reinforced
sutures might be required in case of residual bleeding (52).
Transaxillary/subclavian access. For transaxillary access, the
sheath is introduced through the axillary and subclavian
arteries to the aorta (53). Given the angled course of the
subclavian artery at the offspring of the vertebral artery, use
of a more kink-resistant sheath is advised for valve delivery.
In the absence of calciﬁcation, the artery diameter should
be at least 6 mm for an 18-F sheath. In patients with
a patent left internal mammary artery graft, the diameter
should be at least 7.5 mm to allow continuous ﬂow besides
the sheath. As an alternative, the sheath can be withdrawn
distal to the ostium of the graft after the valve has been
introduced in the ascending aorta. Surgical exposure of the
subclavian artery has been routine (34,38,54,55) and
familiar to most cardiac surgeons as it is used routinely for
arterial cannulation for extracorporeal circulation in more
complex redo procedures. Recently, even a fully percuta-
neous procedure has been described without a surgical
cutdown (56,57).
Direct aortic access. Recently, the direct transaortic
approach has become increasingly popular for implantation
of the Medtronic CoreValve but also the Edwards SAPIEN
and SAPIEN XT valves (58–61). Depending on the
Figure 7. Thrombus Formation After Protamine Administration and Balloon Inﬂation
This patient had ongoing bleeding from the iliofemoral artery despite insertion of 3 ProGlides. Protamine and 10 min of crossover balloon occlusion (A) were followed
by implantation of a 9  60-mm covered stent (Fluency Plus, Bard Canada Inc., Mississauga, Canada) was carried out. Subsequent angiography showed a distal
thrombus (B, arrows), which was treated with reheparinization. Recovery was uneventful.
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651anatomic position of the ascending aorta, the angulation of
the aorta, and the location of calciﬁcations, access is obtained
by either a limited J-shaped sternotomy or a right-sided
mini-thoracotomy and the proximal ascending aorta is
exposed. No double lumen tube ventilation is needed. The
sheath is inserted in a soft spot that is relatively free of
disease, which can often be found even in a heavily calciﬁed
aorta (62). For the Medtronic CoreValve, the puncture site
should be at least 6 to 7 cm above the aortic valve to allow
complete deployment of the frame outside the sheath. Two
purse-string sutures with or without Teﬂon pledgets are
placed and the aorta is punctured. The valve is still
implanted in a retrograde fashion, and positioning and
deployment are similar to a more peripheral approach.
Transaortic access may have some advantages compared
with femoral or transaxillary access. The large-bore sheath is
directly inserted in a large-caliber vessel, avoiding smaller
arteries like the iliofemoral or the subclavian artery, thus
reducing the risk of complications. Furthermore, in some
patients, the approach to the aortic valve is a direct straight
line, which may facilitate the positioning of the prosthesis,
especially in a horizontal root.
Transcarotid. Very limited experience exists with surgical
access via the carotid artery. In a small series of 12 patients,
the procedure was successful in all, there was no mortality,
but 1 patient had a stroke (63). The proximal part of the left
common carotid artery is relatively easily accessible through
a small incision in the neck using local anesthesia. The
patient should tolerate temporary unilateral carotidocclusion, having adequate anterior communicating artery at
the circle of Willis. Passive antegrade carotid perfusion
through a temporary shunt into the common carotid has
been used to ensure adequate cerebral perfusion during the
procedure (64). Further research is needed to clarify whether
this approach is an alternative for patients who do not meet
the criteria for any other access route.
Summary
Transfemoral access can be considered the least invasive
approach for arterial access and therefore is generally the
preferred means of access for TAVI.
Despite ongoing decreases in sheath diameter, some
patients will not be suitable. Alternative access options
include direct aortic, transapical, transaxillary, and, more
recently, transcarotid access. Part 2 of this review will focus
on incidence, risk factors, relevance, and treatment of
speciﬁc vascular complications.
Reprint requests and correspondence: Dr. John G. Webb, St.
Paul’s Hospital, 1081 Burrard Street, Vancouver, British Columbia
V6Z1Y6, Canada. E-mail: john.webb@vch.ca.
REFERENCES
1. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve
implantation for aortic stenosis in patients who cannot undergo surgery.
N Engl J Med 2010;363:1597–607.
Toggweiler et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 7 , 2 0 1 3
Vascular Complications in TAV J U L Y 2 0 1 3 : 6 4 3 – 5 3
6522. Thomas M. The global experience with percutaneous aortic valve
replacement. J Am Coll Cardiol Intv 2010;3:1103–9.
3. Toggweiler S, Humphries KH, Lee M, et al. 5-Year outcome
after transcatheter aortic valve implantation. J Am Coll Cardiol 2012;
61:413–9.
4. Smith CR, Leon MB, Mack M, et al. Transcatheter versus surgical
aortic valve replacement in high-risk patients. N Engl J Med 2011;364:
2187–98.
5. Raphael M, Hartnell G. Femoral artery catheterization and retroperi-
toneal haematoma formation. Clin Radiol 2001;56:933–4; author reply
934–5.
6. Kim D, Orron DE, Skillman JJ, et al. Role of superﬁcial femoral artery
puncture in the development of pseudoaneurysm and arteriovenous
ﬁstula complicating percutaneous transfemoral cardiac catheterization.
Cathet Cardiovasc Diagn 1992;25:91–7.
7. Gabriel M, Pawlaczyk K, Waliszewski K, Krasinski Z, Majewski W.
Location of femoral artery puncture site and the risk of post-
catheterization pseudoaneurysm formation. Int J Cardiol 2007;120:
167–71.
8. Owen AR, Roditi GH. Peripheral arterial disease: the evolving role of
non-invasive imaging. Postgrad Med J 2011;87:189–98.
9. Heijenbrok-Kal MH, Kock MC, Hunink MG. Lower extremity arterial
disease: multidetector CT angiography meta-analysis. Radiology 2007;
245:433–9.
10. Willson AB, Webb JG, Labounty TM, et al. 3-dimensional aortic
annular assessment by multidetector computed tomography predicts
moderate or severe paravalvular regurgitation after transcatheter aortic
valve replacement: a multicenter retrospective analysis. J Am Coll
Cardiol 2012;59:1287–94.
11. Leipsic J, Wood D, Manders D, et al. The evolving role of MDCT in
transcatheter aortic valve replacement: a radiologists’ perspective. AJR
Am J Roentgenol 2009;193:W214–9.
12. Toggweiler S, Gurvitch R, Leipsic J, et al. Percutaneous aortic valve
replacement. Vascular outcomes with a fully percutaneous procedure.
J Am Coll Cardiol 2012;59:113–8.
13. Kubo S, Tadamura E, Yamamuro M, et al. Thoracoabdominal-aor-
toiliac MDCT angiography using reduced dose of contrast material.
AJR Am J Roentgenol 2006;187:548–54.
14. Nietlispach F, Leipsic J, Al-Bugami S, Masson JB, Carere RG,
Webb JG. CT of the ilio-femoral arteries using direct aortic contrast
injection: proof of feasibility in patients screened towards percutaneous
aortic valve replacement. Swiss Med Wkly 2009;139:458–62.
15. Barrett JF, Keat N. Artifacts in CT: recognition and avoidance.
Radiographics 2004;24:1679–91.
16. Collins R, Burch J, Cranny G, et al. Duplex ultrasonography, magnetic
resonance angiography, and computed tomography angiography for
diagnosis and assessment of symptomatic, lower limb peripheral arterial
disease: systematic review. BMJ 2007;334:1257.
17. Klasen J, Blondin D, Schmitt P, et al. Nonenhanced ECG-gated
quiescent-interval single-shot MRA (QISS-MRA) of the lower
extremities: comparison with contrast-enhanced MRA. Clin Radiol
2012;67:441–6.
18. Arthurs ZM, Bishop PD, Feiten LE, Eagleton MJ, Clair DG,
Kashyap VS. Evaluation of peripheral atherosclerosis: a comparative
analysis of angiography and intravascular ultrasound imaging. J Vasc
Surg 2010;51:933–8; discussion 939.
19. Eggebrecht H, Kahlert P, Thielmann M, Plicht B, Erbel R. Usefulness
of a novel balloon-expandable vascular sheath for facilitated large-bore
arterial access for transcatheter aortic valve implantation. Euro-
Intervention 2011;6:893–4.
20. Harrison GJ, How TV, Vallabhaneni SR, et al. Guidewire stiffness:
what’s in a name? J Endovasc Ther 2011;18:797–801.
21. Kurra V, Schoenhagen P, Roselli EE, et al. Prevalence of signiﬁcant
peripheral artery disease in patients evaluated for percutaneous aortic
valve insertion: preprocedural assessment with multidetector computed
tomography. J Thorac Cardiovasc Surg 2009;137:1258–64.
22. Caceres M, Braud R, Roselli EE. The axillary/subclavian artery access
route for transcatheter aortic valve replacement: a systematic review of
the literature. Ann Thorac Surg 2012;93:1013–8.
23. Grube E, Schuler G, Buellesfeld L, et al. Percutaneous aortic valve
replacement for severe aortic stenosis in high-risk patients using thesecond- and current third-generation self-expanding CoreValve pros-
thesis: device success and 30-day clinical outcome. J Am Coll Cardiol
2007;50:69–76.
24. Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day outcomes
following transcatheter aortic valve implantation using the third
generation (18 Fr) CoreValve revalving system: results from the mul-
ticentre, expanded evaluation registry 1-year following CE mark
approval. EuroIntervention 2008;4:242–9.
25. Webb JG, Altwegg L, Boone RH, et al. Transcatheter aortic valve
implantation: impact on clinical and valve-related outcomes. Circulation
2009;119:3009–16.
26. Toggweiler S, Webb J. Challenges in transcatheter aortic valve
implantation. Swiss Med Wkly 2012;142:w13735.
27. Arthurs ZM, Starnes BW, Sohn VY, Singh N, Andersen CA. Ultra-
sound-guided access improves rate of access-related complications for
totally percutaneous aortic aneurysm repair. Ann Vasc Surg 2008;22:
736–41.
28. Ben-Dor I, Maluenda G, Mahmoudi M, et al. A novel, minimally
invasive access technique versus standard 18-gauge needle set for
femoral access. Catheter Cardiovasc Interv 2012;79:1180–5.
29. Carere RG, Webb JG, Ahmed T, Dodek AA. Initial experience using
Prostar: a new device for percutaneous suture-mediated closure of
arterial puncture sites. Cathet Cardiovasc Diagn 1996;37:367–72.
30. Krajcer Z, Howell M. A novel technique using the percutaneous
vascular surgery device to close the 22 French femoral artery entry site
used for percutaneous abdominal aortic aneurysm exclusion. Catheter
Cardiovasc Interv 2000;50:356–60.
31. Starnes BW, Andersen CA, Ronsivalle JA, Stockmaster NR,
Mullenix PS, Statler JD. Totally percutaneous aortic aneurysm repair:
experience and prudence. J Vasc Surg 2006;43:270–6.
32. Jahnke T, Schafer JP, Charalambous N, et al. Total percutaneous
endovascular aneurysm repair with the dual 6-F Perclose-AT pre-
closing technique: a case-control study. J Vasc Interv Radiol 2009;20:
1292–8.
33. Lee WA, BrownMP, Nelson PR, Huber TS. Total percutaneous access
for endovascular aortic aneurysm repair (“Preclose” technique). J Vasc
Surg 2007;45:1095–101.
34. Grube E, Buellesfeld L, Mueller R, et al. Progress and current status of
percutaneous aortic valve replacement: results of three device genera-
tions of the CoreValve Revalving system. Circ Cardiovasc Interv 2008;
1:167–75.
35. Bleiziffer S, Ruge H, Mazzitelli D, et al. Results of percutaneous and
transapical transcatheter aortic valve implantation performed by
a surgical team. Eur J Cardiothorac Surg 2009;35:615–20.
36. Van Mieghem NM, Nuis RJ, Piazza N, et al. Vascular complications
with transcatheter aortic valve implantation using the 18 Fr Medtronic
CoreValve System: the Rotterdam experience. EuroIntervention 2010;
5:673–9.
37. Tchetche D, Dumonteil N, Sauguet A, et al. Thirty-day outcome and
vascular complications after transarterial aortic valve implantation using
both Edwards Sapien and Medtronic CoreValve bioprostheses in
a mixed population. EuroIntervention 2010;5:659–65.
38. Tamburino C, Capodanno D, Ramondo A, et al. Incidence and
predictors of early and late mortality after transcatheter aortic valve
implantation in 663 patients with severe aortic stenosis. Circulation
2011;123:299–308.
39. Gurvitch R, Toggweiler S, Willson AB, et al. Outcomes and compli-
cations of transcatheter aortic valve replacement using a balloon
expandable valve according to the Valve Academic Research Consor-
tium (VARC) guidelines. EuroIntervention 2011;7:41–8.
40. Nuis RJ, van Mieghem NM, van der Boon RM, et al. Effect of expe-
rience on results of transcatheter aortic valve implantation using
a Medtronic CoreValve System. Am J Cardiol 2011;107:1824–9.
41. Stahli BE, Bunzli R, Grunenfelder J, et al. Transcatheter Aortic Valve
Implantation (TAVI) outcome according to standardized endpoint
deﬁnitions by the Valve Academic Research Consortium (VARC).
J Invasive Cardiol 2011;23:307–12.
42. Baim DS, Knopf WD, Hinohara T, et al. Suture-mediated closure of
the femoral access site after cardiac catheterization: results of the suture
to ambulate aNd discharge (STAND I and STAND II) trials. Am J
Cardiol 2000;85:864–9.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 7 , 2 0 1 3 Toggweiler et al.
J U L Y 2 0 1 3 : 6 4 3 – 5 3 Vascular Complications in TAV
65343. Torsello GB, Kasprzak B, Klenk E, Tessarek J, Osada N,
Torsello GF. Endovascular suture versus cutdown for endovascular
aneurysm repair: a prospective randomized pilot study. J Vasc Surg
2003;38:78–82.
44. Applegate RJ, Grabarczyk MA, Little WC, et al. Vascular closure
devices in patients treated with anticoagulation and IIb/IIIa receptor
inhibitors during percutaneous revascularization. J Am Coll Cardiol
2002;40:78–83.
45. Rinder MR, Tamirisa PK, Taniuchi M, Kurz HI, Mumm K,
Lasala JM. Safety and efﬁcacy of suture-mediated closure after percu-
taneous coronary interventions. Catheter Cardiovasc Interv 2001;54:
146–51.
46. Osten MD, Feindel C, Greutmann M, et al. Transcatheter aortic valve
implantation for high risk patients with severe aortic stenosis using the
Edwards Sapien balloon-expandable bioprosthesis: a single centre study
with immediate and medium-term outcomes. Catheter Cardiovasc
Interv 2010;75:475–85.
47. Haas PC, Krajcer Z, Diethrich EB. Closure of large percutaneous access
sites using the Prostar XL Percutaneous Vascular Surgery device.
J Endovasc Surg 1999;6:168–70.
48. Hayashida K, Lefevre T, Chevalier B, et al. True percutaneous approach
for transfemoral aortic valve implantation using the Prostar XL device:
impact of learning curve on vascular complications. J Am Coll Cardiol
Intv 2012;5:207–14.
49. Sharp AS, Michev I, Maisano F, et al. A new technique for vascular
access management in transcatheter aortic valve implantation. Catheter
Cardiovasc Interv 2010;75:784–93.
50. Genereux P, Kodali S, Leon MB, et al. Clinical outcomes using a new
crossover balloon occlusion technique for percutaneous closure after
transfemoral aortic valve implantation. J Am Coll Cardiol Intv 2011;4:
861–7.
51. Lichtenstein SV, Cheung A, Ye J, et al. Transapical transcatheter aortic
valve implantation in humans: initial clinical experience. Circulation
2006;114:591–6.
52. Walther T, Mollmann H, van Linden A, Kempfert J. Transcatheter
aortic valve implantation transapical: step by step. Semin Thorac Car-
diovasc Surg 2011;23:55–61.
53. Ruge H, Lange R, Bleiziffer S, et al. First successful aortic valve
implantation with the CoreValve ReValving System via right subclavian
artery access: a case report. Heart Surg Forum 2008;11:E323–4.54. Eltchaninoff H, Prat A, Gilard M, et al. Transcatheter aortic valve
implantation: early results of the FRANCE (FRench Aortic National
CoreValve and Edwards) registry. Eur Heart J 2011;32:191–7.
55. Cioni M, Taramasso M, Giacomini A, et al. Transaxillary approach:
short- and mid-term results in a single-center experience. Innovations
(Phila) 2011;6:361–5.
56. van Mieghem NM, Luthen C, Oei F, et al. Completely percutaneous
transcatheter aortic valve implantation through transaxillary route: an
evolving concept. EuroIntervention 2012;7:1340–2.
57. Schafer U, Ho Y, Frerker C, et al. Direct percutaneous access technique
for transaxillary transcatheter aortic valve implantation: “the Hamburg
Sankt Georg approach”. J Am Coll Cardiol Intv 2012;5:477–86.
58. Bapat V, Attia R. Transaortic transcatheter aortic valve implantation:
step-by-step guide. Semin Thorac Cardiovasc Surg 2012;24:206–11.
59. Soppa G, Roy D, Brecker S, Jahangiri M. Early experience with the
transaortic approach for transcatheter aortic valve implantation. J Thorac
Cardiovasc Surg 2012;143:1225–7.
60. Etienne PY, Papadatos S, El Khoury E, Pieters D, Price J, Glineur D.
Transaortic transcatheter aortic valve implantation with the Edwards
SAPIEN valve: feasibility, technical considerations, and clinical
advantages. Ann Thorac Surg 2011;92:746–8.
61. Bruschi G, de Marco F, Botta L, et al. Direct aortic access for trans-
catheter self-expanding aortic bioprosthetic valves implantation. Ann
Thorac Surg 2012;94:497–503.
62. Bapat VN, Attia RQ , Thomas M. Distribution of calcium in the
ascending aorta in patients undergoing transcatheter aortic valve
implantation and its relevance to the transaortic approach. J Am Coll
Cardiol Intv 2012;5:470–6.
63. Modine T, Sudre A, Delhaye C, et al. Transcutaneous aortic valve
implantation using the left carotid access: feasibility and early clinical
outcomes. Ann Thorac Surg 2012;93:1489–94.
64. Guyton R, Block P, Thourani V, Lerakis S, Babaliaros V. Carotid artery
access for transcatheter aortic valve replacement. Catheter Cardiovasc
Interv; 2012 Aug 6 [E-pub ahead of print].Key Words: aortic stenosis - transcatheter aortic valve
implantation - transcatheter aortic valve replacement -
vascular complications.
